Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Short Interest Update

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) was the target of a significant decline in short interest during the month of May. As of May 31st, there was short interest totalling 16,800 shares, a decline of 33.3% from the May 15th total of 25,200 shares. Currently, 0.6% of the company’s stock are sold short. Based on an average trading volume of 412,500 shares, the short-interest ratio is currently 0.0 days.

Institutional Trading of Kiora Pharmaceuticals

An institutional investor recently raised its position in Kiora Pharmaceuticals stock. ADAR1 Capital Management LLC boosted its stake in shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) by 1.9% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 200,221 shares of the company’s stock after purchasing an additional 3,670 shares during the period. ADAR1 Capital Management LLC owned approximately 6.67% of Kiora Pharmaceuticals worth $661,000 at the end of the most recent quarter. 76.97% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Kiora Pharmaceuticals in a research report on Friday, March 28th.

Kiora Pharmaceuticals Trading Down 0.3%

NASDAQ:KPRX opened at $3.01 on Tuesday. The company has a market capitalization of $9.16 million, a P/E ratio of -1.04 and a beta of -0.68. Kiora Pharmaceuticals has a 12 month low of $2.51 and a 12 month high of $5.45. The firm has a fifty day simple moving average of $3.08 and a 200-day simple moving average of $3.29.

Kiora Pharmaceuticals (NASDAQ:KPRX) last released its earnings results on Friday, May 9th. The company reported ($0.52) EPS for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.25. Equities analysts forecast that Kiora Pharmaceuticals will post 1.28 EPS for the current year.

Kiora Pharmaceuticals Company Profile

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.